Phocas Financial Corp. Sells 63,485 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Phocas Financial Corp. lessened its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 5.9% during the 3rd quarter, Holdings Channel reports. The fund owned 1,015,190 shares of the company’s stock after selling 63,485 shares during the period. Phocas Financial Corp.’s holdings in Amneal Pharmaceuticals were worth $8,446,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in AMRX. Vanguard Group Inc. lifted its position in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after acquiring an additional 85,846 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Amneal Pharmaceuticals by 12.4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after acquiring an additional 1,179,830 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after acquiring an additional 641,405 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 1.9% in the second quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock worth $16,954,000 after buying an additional 50,000 shares during the last quarter. Finally, BlackBarn Capital Partners LP lifted its stake in shares of Amneal Pharmaceuticals by 41.5% during the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after buying an additional 586,703 shares during the period. Institutional investors own 31.82% of the company’s stock.

Analyst Ratings Changes

AMRX has been the topic of several research analyst reports. Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research note on Friday, September 6th. Finally, Barclays increased their target price on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ AMRX opened at $8.33 on Tuesday. Amneal Pharmaceuticals, Inc. has a 12-month low of $4.16 and a 12-month high of $9.48. The business’s fifty day simple moving average is $8.57 and its 200-day simple moving average is $7.68.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.